2021 annual financial data
Inhibikase Therapeutics 2021 Net margin
Direct answer
Net margin was -477.52%.
Operating income was -14.77M USD and net income was -14.81M USD.
Operating cash flow was -14.3M USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 3.1M USD
- Operating income
- -14.77M USD
- Net income
- -14.81M USD
- Operating cash flow
- -14.3M USD
Explore related company data
View all 2021 financial metricsView RevenueView Operating incomeView Net incomeView Operating cash flowView Revenue growthView Operating income growthView Net income growthView Operating cash flow growthView Operating marginView Operating cash flow marginView all Inhibikase Therapeutics financial years